MMIT Reality Check on COPD (Apr 2020)

According to our recent payer coverage analysis for glaucoma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for glaucoma treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered without utilization management restrictions.

Trends: In March 2020, the FDA approved Allergan plc’s Durysta (bimatoprost implant) 10 mcg to treat open-angle glaucoma or ocular hypertension. This is the first intracameral biodegradable sustained-release implant for the indication.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

young-women-hand-scratch-the-itch-on-the-arm-healthcare-and-medicine
May 20

MMIT Reality Check on Atopic Dermatitis

Read More
May 13

MMIT Reality Check on Narcolepsy

Read More
nurse-doing-blood-test
May 6

MMIT Reality Check on Hemophilia B (Factor IX)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today